Antibiotic Resistance Crisis Deepens in the UK: Private Prescribing Blamed for Rising Infections and Deaths
Despite a slight dip in overall antibiotic use within the NHS, England is facing a terrifying surge in antibiotic-resistant infections and fatalities, according to a stark warning from the UK Health Security Agency (UKHSA). But here's where it gets controversial: private prescribing practices are being pinpointed as a major culprit, potentially undermining national efforts to combat this growing threat.
The agency's latest English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) report for 2024-2025 paints a grim picture. Resistant bloodstream infections (bacteraemia) are on the rise, with a staggering 9.3% increase from 18,740 cases in 2023 to 20,484 in 2024. That's nearly 400 new cases every single week. Even more alarmingly, deaths linked to these resistant infections jumped by 16.6%, from 2,041 to 2,379 in the same period.
And this is the part most people miss: This crisis isn't just a distant threat; it's happening right here, right now, in the UK. Experts like Dr. Catrin Moore, a leading voice in global health, emphasize that antimicrobial resistance (AMR) is an urgent healthcare crisis, not confined to low- and middle-income countries. The widening gap in resistant infections between the most and least deprived communities, growing from 29% in 2019 to 47% in 2024, is particularly concerning, highlighting the deep-rooted social inequalities fueling this problem.
The UK government's five-year national action plan on AMR, launched in May 2024, acknowledges the gravity of the situation. It recognizes effective antimicrobials as the cornerstone of modern medicine and aims to contain, control, and mitigate AMR by 2040. However, the plan's success hinges on addressing the alarming rise in private antibiotic prescribing.
While NHS primary care antibiotic use saw a modest decline from 14.21 to 13.96 daily defined doses per 1000 inhabitants per day (DID) between 2019 and 2024, private dispensing in community pharmacies more than doubled during the same period, soaring from 1.95 to 3.93 DID. This surge in private prescriptions has led to a 10.7% overall increase in primary care antibiotic use, with 22% of antibiotics now dispensed privately in 2024.
The inclusion of Pharmacy First prescribing data in the latest ESPAUR report for the first time reveals that this service accounts for 4% of primary care antibiotic prescriptions. While proponents like Tase Oputu, chair of the Royal Pharmaceutical Society England board, argue that Pharmacy First follows evidence-based clinical pathways to ensure responsible antibiotic use, critics worry about the potential for overprescribing in a private setting.
Is private prescribing a necessary evil or a dangerous loophole? Dr. Jonathan Cox, a microbiology expert, urges private practitioners to consider the long-term consequences of inappropriate prescribing. He emphasizes that reducing unnecessary antibiotic use and upholding antimicrobial stewardship principles are shared responsibilities.
The UK government, experts agree, must urgently invest in research and development of new antimicrobials and streamline regulatory processes to bring these innovations to market. The fight against AMR demands a multi-pronged approach, addressing both public and private healthcare sectors, to safeguard the effectiveness of these life-saving drugs for future generations.
What do you think? Is private prescribing a major contributor to the antibiotic resistance crisis? How can we ensure responsible antibiotic use across all healthcare settings? Share your thoughts in the comments below.
